For the first time, a pharmacotherapy for overweight and obesity has reduced cardiovascular events in patients with established cardiovascular disease in the absence of type 2 diabetes.
The lipid-lowering drug’s treatment effect was greater in this prespecified analysis of high-risk patients without a prior cardiac event than in the overall trial’s secondary prevention cohort.
The artificial intelligence model appropriately answered a large majority of common patient questions about heart health in a preliminary study. But many questions remain before clinical use is a possibility.
Randomized trial evidence that weight loss can yield cardiovascular benefits independent of antidiabetic effects has been elusive. Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The federal task force’s revised recommendations put it in step with most other guidelines — and with the preponderance of recent evidence.
Five prior attempts to gain U.S. regulatory approval for nonprescription access to statin therapy have failed. A novel technology-assisted approach is showing promise where past efforts came up short.
For the first time, the gut microbe-dependent metabolite TMAO has been shown to predict incident coronary artery disease in a large prospective population study of apparently healthy adults.
A deeper dive into the large randomized trial finds no benefit with even the highest blood levels of EPA, casting further doubt on the results of the REDUCE-IT trial and a risk-reducing role for fish oil.
We share our experience providing safe and routine access to phase II cardiac rehabilitation to patients across nine regional cardiac rehab centers using inclusive telemedicine methods and resourceful center-based care.
Detailed findings from this large outcomes study of omega-3 carboxylic acid have renewed scrutiny over potential confounding effects of the mineral oil placebo used in the earlier REDUCE-IT trial.